Core Scientific appoints Jim Nygaard as CFO effective March 17; Sterling departs May 1

Core Scientific, Inc./tx

Jim Nygaard named EVP, CFO effective March 17; 30 years of investment banking/M&A expertise from XMS Capital and Morgan Stanley.
Denise Sterling, who guided Core Scientific through Ch.11 and raised over $1B via convertible notes, departs May 1 for seamless transition.
Nygaard receives $600k base salary, 100% target bonus, and 819,672 time-vesting RSUs (33% vest per year starting March 2026).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James P. Nygaard, Jr.

Executive Vice President, Chief Financial Officer

CORZ · Core Scientific, Inc./tx

Effective: 2025-03-17
Filed: March 4, 2025, 6:59 PM ET

On March 2, 2025, the Board of Directors (the “Board”) of Core Scientific, Inc. (the “Company”) approved the appointment of James P. Nygaard, Jr., age 50, as the Company’s Executive Vice President, Chief Financial Officer, effective March 17, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James P. Nygaard, Jr. was appointed as Executive Vice President, Chief Financial Officer at Core Scientific, Inc./tx.

Action: appointed
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

On March 2, 2025, the Board of Directors (the “Board”) of Core Scientific, Inc. (the “Company”) approved the appointment of James P. Nygaard, Jr., age 50, as the Company’s Executive Vice President, Chief Financial Officer, effective March 17, 2025.

View on SEC.gov

Core Scientific, Inc./tx filing history →

Source: SEC EDGAR

accession 0001628280-25-009570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.